Emerald Advisers, LLC Dexcom Inc Transaction History

Emerald Advisers, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$75.49 - $124.16 $2,113 - $3,476	-28 Reduced 1.31%	2,107 $261,000
Q3 2023 Oct 26, 2023	SELL	$86.06 - $137.93 $3,958 - $6,344	-46 Reduced 2.11%	2,135 $199,000
Q2 2023 Jul 25, 2023	SELL	$112.47 - $130.98 $3,486 - $4,060	-31 Reduced 1.4%	2,181 $280,000
Q1 2023 May 04, 2023	SELL	$104.0 - $122.92 $255,008 - $301,399	-2,452 Reduced 52.57%	2,212 $256,000
Q4 2022 Feb 03, 2023	SELL	$84.98 - $122.67 $6,713 - $9,690	-79 Reduced 1.67%	4,664 $528,000
Q3 2022 Oct 25, 2022	SELL	$76.35 - $94.18 $2,824 - $3,484	-37 Reduced 0.77%	4,743 $382,000
Q2 2022 Jul 29, 2022	BUY	$67.99 - $132.89 $243,744 - $476,410	3,585 Added 300.0%	4,780 $356,000
Q1 2022 Apr 29, 2022	SELL	$94.08 - $130.2 $2,163 - $2,994	-23 Reduced 1.89%	1,195 $611,000
Q4 2021 Feb 02, 2022	SELL	$129.87 - $162.82 $93,376 - $117,067	-719 Reduced 37.12%	1,218 $654,000
Q3 2021 Oct 28, 2021	BUY	$106.71 - $143.18 $48,019 - $64,431	450 Added 30.26%	1,937 $1.06 Million
Q2 2021 Jul 29, 2021	BUY	$80.99 - $107.93 $120,432 - $160,491	1,487 New	1,487 $635,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $30.9B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.